Ramsdell J S, Bethea C L, Jaffe R B, Wilson C B, Weiner R I
Neuroendocrinology. 1985 Jun;40(6):518-25. doi: 10.1159/000124124.
One tenable hypothesis for the etiology of the development of prolactin-secreting adenomas is that a decrease in inhibitory dopaminergic regulation leads to increased lactotroph proliferation. Dopamine receptors have been repeatedly characterized on prolactin-secreting adenomas using labelled antagonists as ligands; however, no data are available on characterization of the receptor with a dopaminergic agonist. An agonist was utilized as the radioligand in the present study to permit the direct comparison of the pharmacological characteristics of the binding site with the biological response, the inhibition of prolactin secretion. This comparison has never been reported in tissues from the same species. Binding of the dopamine agonist and alpha-adrenergic antagonist [3H]-dihydroergocryptine ([3H]-DHE) to particulate fractions of surgically resected human prolactin-secreting adenomas was high affinity, monophasic, and saturable. Careful characterization of the [3H]-DHE binding by competitions with a large number of dopaminergic and alpha-adrenergic agents revealed the presence of both dopaminergic and alpha-adrenergic binding sites. The presence of a saturable, high affinity alpha-adrenergic binding site was confirmed with the specific alpha-adrenergic antagonist [3H]-WB4101 as a radioligand. Although the rank order of potency for dopaminergic compounds to compete for [3H]-DHE binding was consistent with an interaction with a dopamine receptor, the inhibitory constants (Ki) calculated from the competitions were higher than expected at an anterior pituitary dopamine receptor. This appeared to be due to the lower affinity of these agents at the alpha-adrenergic sites. The observed potency of dopaminergic compounds was inversely related to the number of alpha-adrenergic sites.(ABSTRACT TRUNCATED AT 250 WORDS)
对于催乳素分泌性腺瘤发生发展的病因,一个合理的假说是抑制性多巴胺能调节的降低导致催乳素细胞增殖增加。使用标记拮抗剂作为配体,已反复对催乳素分泌性腺瘤上的多巴胺受体进行了表征;然而,尚无关于用多巴胺能激动剂表征该受体的数据。在本研究中使用激动剂作为放射性配体,以便将结合位点的药理学特性与生物学反应(催乳素分泌的抑制)进行直接比较。这种比较在来自同一物种的组织中从未有过报道。多巴胺激动剂和α-肾上腺素能拮抗剂[³H]-二氢麦角隐亭([³H]-DHE)与手术切除的人催乳素分泌性腺瘤的微粒体部分的结合具有高亲和力、单相性且可饱和。通过与大量多巴胺能和α-肾上腺素能药物竞争对[³H]-DHE结合进行仔细表征,揭示了多巴胺能和α-肾上腺素能结合位点的存在。用特异性α-肾上腺素能拮抗剂[³H]-WB4101作为放射性配体证实了可饱和、高亲和力α-肾上腺素能结合位点的存在。尽管多巴胺能化合物竞争[³H]-DHE结合的效力排序与与多巴胺受体的相互作用一致,但从竞争中计算出的抑制常数(Ki)高于垂体前叶多巴胺受体的预期值。这似乎是由于这些药物在α-肾上腺素能位点的亲和力较低。观察到的多巴胺能化合物的效力与α-肾上腺素能位点的数量呈负相关。(摘要截断于250字)